

Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

A. Disclosure obligation (tick box to note which disclosure obligation applies)

☐

Initial disclosure (complete Parts A, B, C, D, F, and G of this notice)

☒

Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice)

B. Preliminary

1.	Name	Dr John Douglas Wilson
2.	Name of issuer	Neuren Pharmaceuticals Limited
3.	Name of related body corporate (if applicable)	Ridgefield Family Trust
4.	Position you hold in the issuer	Director
5.	Date of this disclosure notice	14 March 2005

C. Nature of relevant interest

6.	Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b))	Ridgefield Family Trust
7.	Class and type of security (as required by regulation 6B or regulation 8)	Ordinary Shares
8.	Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))	Relevant interest as a trustee of the Ridgefield Family Trust

D. Date (for initial disclosure)

9.	Date of disclosure obligation (as required by regulation 6C)	N/A
----	--	-----

E. Transaction (for ongoing disclosure)

10.	Date of last disclosure (as required by regulation 13)	N/A
11.	Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)	4 February 2005
12.	Number of transactions (as required by regulation 12(2), if applicable)	135,000
13.	Nature or type of transaction (as required by regulation 11(1)(a))	Ordinary Shares
14.	Consideration (as required by regulation 10)	A\$50,000

15.	Number of securities held prior, set out by class and type (as required by regulation 8)	NIL
16.	Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b))	NIL

F. Extent of relevant interest

17.	Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8)	135,000 Ordinary Shares
-----	---	-------------------------

G. Signature

18.	Signature (as required by regulation 14)	
-----	--	--

Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

A. Disclosure obligation (tick box to note which disclosure obligation applies)

☐

Initial disclosure (complete Parts A, B, C, D, F, and G of this notice)

☒

Ongoing disclosure (complete Parts A, B, C, E, F, and G of this notice)

B. Preliminary

1.	Name	Mr Graeme Howie
2.	Name of issuer	Neuren Pharmaceuticals Limited
3.	Name of related body corporate (if applicable)	N/A
4.	Position you hold in the issuer	Director
5.	Date of this disclosure notice	14 March 2005

C. Nature of relevant interest

6.	Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b))	Mr Graeme Howie
7.	Class and type of security (as required by regulation 6B or regulation 8)	Ordinary Shares
8.	Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))	Relevant interest as director of Neuren Pharmaceuticals Limited

D. Date (for initial disclosure)

9.	Date of disclosure obligation (as required by regulation 6C)	N/A
----	--	-----

E. Transaction (for ongoing disclosure)

10.	Date of last disclosure (as required by regulation 13)	N/A
11.	Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)	4 March 2005
12.	Number of transactions (as required by regulation 12(2), if applicable)	50,000 Ordinary Shares
13.	Nature or type of transaction (as required by regulation 11(1)(a))	Ordinary Shares
14.	Consideration (as required by regulation 10)	A\$16,350.00

15.	Number of securities held prior, set out by class and type (as required by regulation 8)	NIL
16.	Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b))	NIL

F. Extent of relevant interest

17.	Number of securities held now, set out by class and type (as required by regulation 6B or regulation 8)	50,000 Ordinary Shares
-----	---	------------------------

G. Signature

18.	Signature (as required by regulation 14)	
-----	--	--